Status:
COMPLETED
Utility of a Novel Dd-cfDNA Test to Detect Injury in Renal Post-Transplant Patients
Lead Sponsor:
Qure Healthcare, LLC
Collaborating Sponsors:
Natera, Inc.
Conditions:
Transplant;Failure,Kidney
Eligibility:
All Genders
Phase:
NA
Brief Summary
Detecting allograft injury and rejection is critical to preventing graft loss. The current standard of care (SoC) relies on serum creatinine (SC) and biopsy to monitor for and identify kidney injury e...
Detailed Description
Five-year kidney allograft survival rates are estimated to be as low as 71.6%. A leading cause for the high prevalence of graft loss is the delay in detecting allograft injury from active rejection, w...
Eligibility Criteria
Inclusion
- A minimum of 2 years post-residency but no more than 40 years in practice
- Board-certified in internal medicine
- Completion of a nephrology fellowship
- In a private solo or multi-group practice
- Minimum threshold of 5 post-kidney transplant (KT) patients currently seen monthly
- Informed, signed and voluntarily consented to be in the study
Exclusion
- Not board certified in internal medicine
- Have practiced as a board-certified physician for less than 2 or greater than 40 years
- See \<5 post-transplant patients monthly
- Non-English speaking
- Unable to access the internet
Key Trial Info
Start Date :
November 5 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 7 2019
Estimated Enrollment :
175 Patients enrolled
Trial Details
Trial ID
NCT03765203
Start Date
November 5 2018
End Date
January 7 2019
Last Update
September 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
QURE Healthcare
San Francisco, California, United States, 94109